EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations

Dinesh Thapa iD, Mohan Patil, Leon N Warne, Rodrigo Carlessi iD, Marco Falasca iD

Cells · 05.12.2024 · 13 (23) · 2013

DOI: 10.3390/cells13232013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 05.12.2024. Verfasst von Dinesh Thapa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, WA 6102, Australia. Hauptthemen laut MEDLINE: Cannabidiol, Disease Models, Animal, Dextran Sulfate, Colitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Little Green Pharma, Little Green Pharma Pty Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabinoids are emerging as promising treatments for inflammatory diseases such as ulcerative colitis. Specifically, cannabinoid 2 (CB2) receptors, which are upregulated during inflammation, have been distinctively linked to anti-inflammatory and analgesic effects. HU308, a synthetic cannabinoid developed to activate CB2 receptors selectively, aims to minimize unwanted off-target side effects. This study evaluated the effectiveness of both cannabidiol (CBD) and HU308 in mouse models of dextran sodium sulphate (DSS)-induced colitis, which mimic the acute and chronic phases of ulcerative colitis. Mice were treated with DSS in drinking water (four percent for the acute model and one to two percent for the chronic model) to induce colitis, as indicated by increased disease activity index (DAI) scores and inflammatory markers. Treatment with 60 mg/kg of CBD, but not lower doses, significantly reduced colitis symptoms, such as inflammation, cytokine levels, and MPO activity, while also normalizing glucagon-like peptide-1 (GLP-1) levels. HU308 showed comparable efficacy to high-dose CBD (60 mg/kg) but at a much lower dose (2.5 mg/kg), without observable toxicity. HU308 effectively normalized DAI scores, colon inflammation, ammonia levels, and GLP-1 expression in both colitis models. These results suggest that both CBD and HU308 are promising treatments for ulcerative colitis. However, HU308 demonstrates enhanced therapeutic potential by achieving similar outcomes at a fraction of the dose required for CBD, reducing the risk of off-target side effects. The ability of HU308 to modulate GLP-1, a biomarker of gut endocrine function, further underscores its promise as a novel treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolDisease Models, AnimalDextran SulfateColitisAnimalsMiceChronic DiseaseCannabinoidsAcute DiseaseMaleMice, Inbred C57BLGlucagon-Like Peptide 1CytokinesReceptor, Cannabinoid, CB2Colitis, UlcerativeColonFemale

Stichwörter der Autor:innen

HU308cannabidiol (CBD)cannabinoid 2 receptorinflammationinflammatory bowel disease (IBD)ulcerative colitis

Substanzen

CannabidiolDextran SulfateHU 308CannabinoidsGlucagon-Like Peptide 1CytokinesReceptor, Cannabinoid, CB2

Autor:innen und Institutionen

  • Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, WA 6102, Australia.
  • College of Science, Health, Engineering and Education, Murdoch University, Perth, WA 6150, Australia.
  • Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia.
  • Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy.

ORCID-Profile: Dinesh Thapa, Rodrigo Carlessi, Marco Falasca

Förderung

  • Little Green Pharma
  • Little Green Pharma Pty Ltd.

Zitieren

APA

Thapa, D., Patil, M., Warne, L. N., Carlessi, R., & Falasca, M. (2024). Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations. Cells, 13(23), 2013. https://doi.org/10.3390/cells13232013

Vancouver

Thapa D, Patil M, Warne LN, Carlessi R, Falasca M. Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations. Cells. 2024;13(23):2013. doi:10.3390/cells13232013

BibTeX
@article{Thapa2024,
  author = {Thapa, Dinesh and Patil, Mohan and Warne, Leon N and Carlessi, Rodrigo and Falasca, Marco},
  title = {Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {23},
  pages = {2013},
  doi = {10.3390/cells13232013}
}
Kostenlos starten →